Point-of-care testing for hepatitis B virus infection in a community-based occupational health cohort in the Western Cape Province, South Africa- Nafiisah Chotun

Conference on Liver Disease in Africa (COLDA) 2018

Management of Hepatocellular Carcinoma in Africa- Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD

Conference on Liver Disease in Africa (COLDA) 2018

Large-scale discovery and validation of blood and urinary discriminant metabolites as potential biomarkers for the diagnosis hepatocellular carcinoma in West Africa -Mei Ran Abellona

Conference on Liver Disease in Africa (COLDA) 2018

Management of end-stage Liver Disease in Resource Limited Settings- Mark Sonderup

Conference on Liver Disease in Africa (COLDA) 2018

The establishment of hepatitis B care and treatment clinics in the United Republic of Tanzania: A demonstration project following WHO guidelines- John Rwegasha

Conference on Liver Disease in Africa (COLDA) 2018

New diagnostics to improve diagnosis of liver disease- Francesco Marinucci

Conference on Liver Disease in Africa (COLDA) 2018

NOhep Visionaries in Africa: Medical professionals leading the way towards hepatitis elimination- Jessica Hicks

Conference on Liver Disease in Africa (COLDA) 2018

Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MD

International Workshop on NASH Biomarkers 2018

Pathways and priorities for biomarker assessment- Peter Stein, MD

International Workshop on NASH Biomarkers 2018

Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala

International Workshop on NASH Biomarkers 2018

Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD

International Workshop on NASH Biomarkers 2018

Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD

International Workshop on NASH Biomarkers 2018

Quality standards for imaging studies- Claude Sirlin, MD

International Workshop on NASH Biomarkers 2018

Case definitions for use as reference standards- Mohammed Siddiqui, MD

International Workshop on NASH Biomarkers 2018

Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MD

International Workshop on NASH Biomarkers 2018

A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit Kar

International Workshop on NASH Biomarkers 2018

Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel Daniels

International Workshop on NASH Biomarkers 2018

What is needed to link device approval to clinical application approval?- David Litwack, PhD

International Workshop on NASH Biomarkers 2018

Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response for pre-cirrhotic NASH- Brent Tetri, MD

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhD

International Workshop on NASH Biomarkers 2018

Defining therapeutic response in precirrhotic and cirrhotic NASH- Manal Abdelmalek , MD

International Workshop on NASH Biomarkers 2018

The clinical need for integrated assessment of NASH diabetes and heart disease- Arun Sanyal, MD, MBBS

International Workshop on NASH Biomarkers 2018

Use of plasma PRO-C3, PRO-C5, and PRO-C6 for the diagnosis and follow-up of fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD)- iana Leeming

International Workshop on NASH Biomarkers 2018